Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

101. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

102. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients (Abstract)

A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients Central venous catheters (CVCs) are used for vascular access in hemodialysis patients who have no alternative access or are awaiting placement or maturation of a permanent access. The major complications of CVCs are catheter-related bloodstream infection and clotting in the catheter lumen.Parallel-group, randomized, multicenter clinical trial, with patients blinded (...) to study intervention.16 free-standing dialysis facilities in Northern California belonging to a single provider. 303 adult maintenance hemodialysis patients who were using a tunneled cuffed CVC for vascular access.The treatment group received an antibiotic lock containing gentamicin 320 μg/mL in 4% sodium citrate, whereas the control group received the standard catheter lock containing heparin 1,000 U/mL. Both groups received triple-antibiotic ointment on the catheter exit site during dressing changes

2012 EvidenceUpdates Controlled trial quality: uncertain

103. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

104. Diagnosis and management of Heparin induced thrombocytopenia: second edition

Diagnosis and management of Heparin induced thrombocytopenia: second edition Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition - Watson - 2012 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines (...) on the diagnosis and management of heparin‐induced thrombocytopenia: second edition Corresponding Author Aberdeen Royal Infirmary, Aberdeen, UK Correspondence: Dr Henry Watson, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E‐mail: Royal Brompton Hospital, London, UK Oxford University Hospitals, Oxford, UK Corresponding Author Aberdeen Royal Infirmary, Aberdeen, UK Correspondence: Dr Henry Watson, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E‐mail

2012 British Committee for Standards in Haematology

105. Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care

Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care] Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic (...) disease with low molecular weight heparins in adult patients in home care] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Urtasun M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi

2012 Health Technology Assessment (HTA) Database.

106. Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline

Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Article Text Child health Randomised controlled

2012 Evidence-Based Nursing

107. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients (Abstract)

A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients Diagnosing postoperative heparin-induced thrombocytopenia (HIT) in cardiothoracic surgical patients is complicated because of the profound thrombocytopenia that occurs with cardiopulmonary bypass (CPB). CPB predisposes patients to develop a frequent incidence of antibodies directed against platelet factor 4 (PF4)/heparin complexes and HIT (...) . The sensitivity of readily available antibody immunoassays is high, but specificity is quite low. The use of both a clinical probability score and rapid laboratory immunoassay has been shown to increase specificity, which is of particular importance in the CPB setting. Prompt diagnosis is crucial because cessation of heparin and treatment with alternative anticoagulation can reduce the risk of thromboembolic events.We retrospectively reviewed records from cardiothoracic surgical patients whose serum

2012 EvidenceUpdates

108. [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease]

[Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Pichon Riviere A, Augustovski F, Garcia (...) . [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°252. 2012 Authors' objectives To assess the evidence available on the safety, efficacy and other aspects related to coverage polices of the use of heparin-bonding vascular prosthesis for the treatment of peripheral artery occlusion. Authors' conclusions Short and long-term primary and secondary permeability rates

2012 Health Technology Assessment (HTA) Database.

109. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Full Text available with Trip Pro

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Schwenkglenks M, Brazier JE (...) , Szucs TD, Fox KA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of bivalirudin compared with heparin plus glycoprotein IIb/IIIa inhibitor in thienopyridine-treated patients with non-ST-segment

2011 NHS Economic Evaluation Database.

110. Heparin-binding protein: A diagnostic marker of acute bacterial meningitis (Abstract)

Heparin-binding protein: A diagnostic marker of acute bacterial meningitis The early detection of bacterial meningitis is crucial for successful outcome. Heparin-binding protein, a potent inducer of increased vascular permeability, is released from activated neutrophils in severe sepsis.In this study we investigated whether heparin-binding protein levels in cerebrospinal fluid could be used as a diagnostic marker for acute bacterial meningitis.One prospective and one retrospective patient (...) of heparin-binding protein, lactate, protein, glucose, neutrophils, and mononuclear cells. Heparin-binding protein levels were significantly higher (p < .01) in patients with acute bacterial meningitis (median 376 ng/mL, range 12-858 ng/mL) than in patients with viral central nervous system infection (median 4.7 ng/mL, range 3.0-41 ng/mL) or neuroborreliosis (median 3.6 ng/mL, range 3.2-10 ng/mL) or in control patients with a normal cerebrospinal fluid cell count (median 3.5 ng/mL, range 2.4-8.7 ng/mL

2011 EvidenceUpdates

111. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study Full Text available with Trip Pro

Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study General recommendations indicate that, during a carotid artery stenting (CAS), sufficient unfractionated heparin (UFH) has to be given to maintain the activated clotting time between 250 to 300 seconds. Bivalirudin use is able to reduce postprocedural bleedings in percutaneous interventions when compared with UFH. The study purpose (...) was to evaluate, in a randomized study, the safety and efficacy of bivalirudin versus heparin during CAS, using proximal endovascular occlusion (PEO) as a distal protection device.From January 2006 to December 2009, 220 patients undergoing CAS using PEO have been randomly assigned to one of the study arms (control arm: 100 UI/kg UFH or bivalirudin arm: 0.75 mg/kg intravenous bolus and intraprocedural infusion at 1.75 mg/kg/h).Procedural success was achieved in all the patients. No episodes of intraprocedural

2011 EvidenceUpdates Controlled trial quality: uncertain

112. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy (Abstract)

Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy To evaluate the safety and efficacy of bivalirudin compared with heparin for preventing hemofilter occlusion during continuous venovenous hemofiltration (CVVH).Prospective, randomized, double-blind study.University-affiliated hospital.Ten critically ill adults (median age 58 yrs, 70% male) with acute renal failure who, without anticoagulation, experienced hemofilter (...) survival time of 24 hours or less during CVVH.Patients were randomized to receive bivalirudin 2 mg/hour (five patients) or heparin 400 units/hour (five patients) administered prefilter into the extracorporeal circuit.Patients had a median Acute Physiology and Chronic Health Evaluation (APACHE) II score of 24, Sequential Organ Failure Assessment (SOFA) score of 11, and reduced antithrombin activity (75.5 units/dl). Baseline characteristics were not significantly different between groups. Study drug

2011 EvidenceUpdates Controlled trial quality: predicted high

113. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery

A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2011 PedsCCM Evidence-Based Journal Club

114. [Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin - induced thrombocytopenia]

[Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin - induced thrombocytopenia] Biologie des anomalies de l'hémostase: recherche d'anticorps antifacteur 4 plaquettaire [Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin – induced thrombocytopenia] Biologie des anomalies de l'hémostase: recherche d'anticorps antifacteur 4 plaquettaire [Biology of haemostasis disorders: testing for antibodies (...) to platelet factor 4 in a patient with heparin – induced thrombocytopenia] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Biologie des anomalies de l'hémostase: recherche d'anticorps antifacteur 4 plaquettaire. [Biology of haemostasis disorders: testing for antibodies to platelet factor 4

2011 Health Technology Assessment (HTA) Database.

115. Heparin Sodium Injection

Heparin Sodium Injection Drug Approval Package:Heparin Sodium NDA #201370 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Heparin Sodium Injection USP Company: Pfizer Inc. Application No.: 201370 Approval Date: 07/21/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: June 20, 2012 Vision

2011 FDA - Drug Approval Package

116. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies

Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

117. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials

Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

118. Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fon

Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fon Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux | BMJ (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux Article Text Therapeutics Randomised controlled trial Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access

2011 Evidence-Based Medicine

119. Cochrane systematic review: Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis

Cochrane systematic review: Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis Article Text Therapeutics Cochrane systematic review Extended

2011 Evidence-Based Medicine

120. Low-molecular-weight heparin and mortality in acutely ill medical patients. Full Text available with Trip Pro

Low-molecular-weight heparin and mortality in acutely ill medical patients. Although thromboprophylaxis reduces the incidence of venous thromboembolism in acutely ill medical patients, an associated reduction in the rate of death from any cause has not been shown.We conducted a double-blind, placebo-controlled, randomized trial to assess the effect of subcutaneous enoxaparin (40 mg daily) as compared with placebo--both administered for 10±4 days in patients who were wearing elastic stockings

2011 NEJM Controlled trial quality: predicted high